Brenton Taylor Biography and Net Worth

Executive Vice President, Operations and R&D of Sight Sciences

Mr. Taylor has nearly 25 years of experience in medical and energy technology development and operations, overseeing innovation, product development, and manufacturing.

Prior to joining Sight Sciences, he most recently served as Chief Executive Officer at NEXT Energy Technologies, a pioneer in organic photovoltaic (OPV) technology, where he initially joined as Executive Vice President, Engineering in 2021. Prior to this role, Mr. Taylor co-founded Inogen, Inc (Nasdaq: INGN) (“Inogen”), a medical technology company offering innovative respiratory products for use in the homecare setting, where he spent over 20 years and was instrumental in developing and scaling a line of innovative respiratory medical devices to $350 million in annual sales. His last role at Inogen was Executive Vice President, Engineering. Mr. Taylor received a B.S. in microbiology from the University of California, Santa Barbara.

What is Brenton Taylor's net worth?: The estimated net worth of Brenton Taylor is at least $1.41 million as of April 1st, 2026. Mr. Taylor owns 267,807 shares of Sight Sciences stock worth more than $1,414,021 as of May 7th. This net worth approximation does not reflect any other investments that Mr. Taylor may own. Learn More about Brenton Taylor's net worth.
How do I contact Brenton Taylor?: The corporate mailing address for Mr. Taylor and other Sight Sciences executives is 4040 CAMPBELL AVE SUITE 100, MENLO PARK CA, 94025. Sight Sciences can also be reached via phone at 877-266-1144 and via email at [email protected]. Learn More on Brenton Taylor's contact information.
Has Brenton Taylor been buying or selling shares of Sight Sciences?: Within the last three months, Brenton Taylor has sold $10,615.30 in shares of Sight Sciences stock. Most recently, Brenton Taylor sold 2,869 shares of the business's stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $3.70, for a transaction totalling $10,615.30. Following the completion of the sale, the executive vice president now directly owns 267,807 shares of the company's stock, valued at $990,885.90. Learn More on Brenton Taylor's trading history.
Who are Sight Sciences' active insiders?: Sight Sciences' insider roster includes Alison Bauerlein (CFO), Staffan Encrantz (Director), Jesse Selnick (CFO), and Brenton Taylor (Executive Vice President, Operations and R&D). Learn More on Sight Sciences' active insiders.
Are insiders buying or selling shares of Sight Sciences?: In the last year, insiders at the sold shares 30 times. They sold a total of 307,648 shares worth more than $1,746,086.49. The most recent insider tranaction occured on April, 6th when CFO James Rodberg sold 7,231 shares worth more than $25,670.05. Insiders at Sight Sciences own 30.9% of the company. Learn More about insider trades at Sight Sciences.
Information on this page was last updated on 4/6/2026.

Brenton Taylor Insider Trading History at Sight Sciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/1/2026	Sell	2,869	$3.70	$10,615.30	267,807
1/6/2026	Sell	619	$7.48	$4,630.12	170,212
11/17/2025	Sell	14,418	$7.06	$101,791.08	170,831
10/6/2025	Sell	591	$3.37	$1,991.67	185,249

Brenton Taylor Buying and Selling Activity at Sight Sciences

Sight Sciences Company Overview

Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.

Today's Range

Now: $5.36

$4.36

$5.40

50 Day Range

MA: $4.07

$3.45

$5.62

2 Week Range

Now: $5.36

$2.81

$9.24

Volume

308,641 shs

Average Volume

317,056 shs

Market Capitalization

$291.31 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.38